Measurement Comparability Between Modes of Administration of PROMs
Task Force
-
Special Interest Groups
- Biosimilars
- Clinical Outcome Assessment
- Digital Health
- Health Preference Research
- Medical Devices and Diagnostics
- Medication Adherence and Persistence
-
Nutrition Economics
- Oncology
- Open Source Models
- Patient-Centered
- Personalized / Precision Medicine
- Rare Disease
- Real-World Evidence (RWE)
- Statistical Methods in HEOR
-
Task Forces
- Machine Learning Methods in HEOR
- Measurement Comparability Between Modes of Administration of PROMs
- Performance Outcome (PerfO) Assessments
- Systematic Reviews with Cost and Cost-Effectiveness Outcomes
- Value Assessment Frameworks Special Task Force
- Value of Information Analysis for Research Decisions
- Joint ISPE-ISPOR Special Task Force
- Councils & Roundtables
-
Global Groups
-
Consortia
-
Asia Consortium
- Asia Consortium Founding Members
- Asia Consortium Executive Committee
- Asia Consortium Advisory Committee
- Asia Pacific Conference Committee
- Asia Consortium Education Committee
- Asia Consortium Publication Committee
- Asia Consortium Industry Committee
- Asia Consortium HTA Agencies Committee
- HealthNetIndia
- Central & Eastern Europe Consortium
- Latin America Consortium
-
Asia Consortium
- Networks
- Regional Chapters
-
Join an ISPOR Global Member Group
-
Consortia
- Students
-
New Professionals
-
Professional Development Resources
- Good Practices for HTA - What is out there and how do I use it
- ISPOR & AACP Joint Webinar – “Tips for Securing a Post-Doctoral Fellowship”
- You Are Creative: Research is the First Step
- AMCP eDossier System @ FormularyDecisions.com Demo and Practical Application
- Good Practices for a Successful Job Search
- Leveraging The Power Of LinkedIn
- Internships & Fellowships: Career Opportunities for the Future
- My Career Path
- Career Advice Across the Globe
- "My ISPOR Story" - Zeba Khan
- "My ISPOR Story" - Lou Garrison
-
Professional Development Resources
Objective
This task force’s goal is to revisit and update the good practice recommendations from the 2009 ISPOR ePRO Good Research Practices Task Force and the 2014 PRO Mixed Modes Good Research Practices Task Force reports in light of the accumulated evidence of measurement comparability between paper and electronic modes of PRO data collection and between different electronic modes of patient reported outcome measures (PROMs). The task force will provide recommendations related to mixing modes of administration, BYOD, and the need (or otherwise) to proactively demonstrate comparability between modes of administration.
Rationale
With the accumulation of evidence of measurement comparability between and among modes of data collection, as well as the US FDA’s encouragement of electronic data capture, it is appropriate to initiate a new ISPOR Good Practices Task Force to update the 2 previous ISPOR task force reports on the electronic implementation of PROMs in clinical trials (Coons et al 2009; Eremenco et al 2014) in order to provide stakeholders with best practice recommendations that reflect the growing evidence base.
Co-Chairs:
Paul O’Donohoe, MSc
Scientific Lead, eCOA and Mobile Health, Medidata
London, England, UK
David Reasner, PhD
Head, Data Science & Analytics, Imbria Pharmaceuticals
Boston, MA, USA
Leadership Group
Valdo Arnera, MD
Scientific Advisor and General Manager, ERT Geneva,
Geneva, Switzerland
Alexandra I Barsdorf, PhD
Director, Clinical Outcomes Solutions
New York, NY, USA
Serge Bodart, MSc
Chief Commercial Officer (CCO) at IDDI and
Independent eCOA Subject Matter Expert
Brussels, Belgium
Stephen Joel Coons, PhD
Executive Director, Patient-Reported Outcome (PRO) Consortium and
Program Officer, Clinical Outcome Assessment Program
Critical Path Institute
Tucson, AZ, USA
Bill Byrom, PhD
Vice President, Product Strategy and Innovation
Signant Health
London, England, UK
Sonya Eremenco, MA
Acting Director, Electronic Patient-Reported Outcome (ePRO) Consortium and
Associate Director, Patient-Reported Outcome (PRO) Consortium
Critical Path Institute
Tucson, AZ, USA
Sarrit Kovacs, PhD
Lead Clinical Analyst/Team Leader, Division of Clinical Outcome Assessment (DCOA)
Office of Drug Evaluation Science, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration (FDA)
Silver Spring, MD, USA
Jean Paty, PhD
Vice President, Patient-Centered Endpoints, Real-World and Analytic Solutions
QuintilesIMS
New York, NY, USA
Megan Turner, BA
Scientist, COA Implementation
GSK
Collegeville, PA, USA
Sue Vallow, MBA, MA
Executive Director, Patient-Centered Outcomes / PCO Lead, Global Value and Access,
Novartis Oncology
East Hanover, NJ, USA